Skip to main content

Peter Thiel speaks at the New York Times DealBook conference on Nov. 1, 2018, in New York City.

Stephanie Keith/Getty Images

Billionaire venture capitalist Peter Thiel has joined the board of AbCellera Biologics Inc. ahead of an expected Nasdaq IPO filing by the Canadian antibody therapy developer, whose work to find a COVID-19 treatment has captured global attention.

Mr. Thiel, who has backed several startups as they went public, is an existing investor in Vancouver-based AbCellera. He joins the startup’s board two months after it hired investment banks Credit Suisse Group AG, Stifel Financial Corp. and SVB Leerink as the lead underwriters for the Nasdaq initial public offering. His appointment comes a day after former RBC Global Asset Management chief executive officer John Montalbano joined the board, where he will chair the audit committee. AbCellera also said this week it had purchased Trianni Inc., a biotechnology company that uses genetically engineered mice to help discover new antibodies, for US$90-million in cash.

The Globe and Mail first reported in July that AbCellera, which uses a mix of complex technologies to unearth antibody-based drugs more quickly, cheaply and effectively than conventional methods, was considering an IPO. Its registration statement is expected to be made public on the U.S. Securities and Exchange Commission website within days.

Story continues below advertisement

AbCellera has already raised significant sums in 2020 on the strength of partnerships with some of the world’s largest drug companies to identify drug candidates for a range of ailments, including a deal with Eli Lilly and Co. to develop a treatment for the novel coronavirus.

In May, AbCellera secured $175.6-million in development funds from the federal government plus US$105-million in venture capital from leading global life-sciences investors.

AbCellera was spun out from the University of British Columbia’s interdisciplinary Michael Smith Laboratories – where CEO Carl Hansen ran the bioengineering group – in 2012. Using technology developed at the lab, AbCellera speeds up the process to isolate and identify antibodies created by humans to fight infections.

Its “antibody discovery engine” process involves passing blood samples from a person who has developed an immunity to a disease through a credit card-sized “microfluidic” device with hundreds of thousands of tiny chambers. Using artificial intelligence, it tests antibodies produced by cells in each chamber simultaneously, homing in on those that have the potential to be developed into drugs.

Within three days of receiving a blood sample from a recovered COVID-19 patient this spring, AbCellera isolated hundreds of antibody candidates for a drug. It cut that to 24 within three weeks and partnered with Eli Lilly to quickly produce a drug for coronavirus patients called bamlanivimab, which was authorized earlier this month by the U.S. Food and Drug Administration for emergency use on patients.

Mr. Thiel is known for his early investments in Facebook and co-founding electronic payment service provider PayPal Holdings Inc. In September, he took data-analytics firm Palantir Technologies Inc. public through a direct listing.

With files from Reuters

Story continues below advertisement

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies